*Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; and †The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):261-70. doi: 10.1097/QAI.0b013e3182a23e9a.
The temporal relationship between incident tuberculosis (TB) and virological outcomes during antiretroviral therapy (ART) is poorly defined. This was studied in a cohort in Cape Town, South Africa.
Data regarding TB diagnoses, ART regimens, and 4-monthly updated viral load (VL) and CD4 count measurements were extracted from a prospectively maintained database. Rates of virological breakthrough (VL > 1000 copies/mL) and failure (VL > 1000 copies/mL on serial measurements) following initial VL suppression were calculated. Poisson models were used to calculate incidence rate ratios (IRRs) and identify risk factors for these virological outcomes.
Incident TB was diagnosed in 391 (28.5%) of 1370 patients during a median of 5.2 years follow-up. Five hundred seventy-eight episodes of virological breakthrough and 231 episodes of virological failure occurred, giving rates of 10.0 episodes per 100 person-years and 4.0 episodes per 100 person-years, respectively. In multivariate analyses adjusted for baseline and time-updated risk factors, TB was an independent risk factor for adverse virological outcomes. These associations were strongly time dependent; the 6-month period following diagnosis of incident TB was associated with a substantially increased risk of virological breakthrough (IRR: 2.3, 95% confidence interval: 1.7 to 3.2) and failure (IRR: 2.6, 95% confidence interval: 1.6 to 4.3) compared with time without a TB diagnosis. Person-time preceding TB diagnosis or more than 6 months after a TB diagnosis was not associated with poor virological outcomes.
Incident TB during ART was strongly associated with poor virological outcomes during the 6-month period following TB diagnosis. Although underlying mechanisms remain to be defined, patients with incident TB may benefit from virological monitoring and treatment adherence support.
抗逆转录病毒治疗(ART)期间发生的结核病(TB)与病毒学结果之间的时间关系尚未明确。本研究在南非开普敦的一个队列中进行。
从一个前瞻性维护的数据库中提取了有关 TB 诊断,ART 方案以及每 4 个月更新的病毒载量(VL)和 CD4 计数测量值的数据。计算了初始 VL 抑制后病毒学突破(VL > 1000 拷贝/mL)和失败(VL > 1000 拷贝/mL的连续测量)的发生率。使用泊松模型计算发病率比(IRR)并确定这些病毒学结果的危险因素。
在中位 5.2 年的随访中,1370 例患者中有 391 例(28.5%)被诊断为活动性结核病。发生了 578 次病毒学突破和 231 次病毒学失败,分别为每 100 人年 10.0 次和每 100 人年 4.0 次。在调整了基线和时间更新的危险因素后,结核病是不良病毒学结果的独立危险因素。这些关联具有强烈的时间依赖性;与无 TB 诊断的时间相比,在诊断出活动性 TB 后的 6 个月内,病毒学突破(IRR:2.3,95%置信区间:1.7 至 3.2)和失败(IRR:2.6,95%置信区间:1.6 至 4.3)的风险大大增加。在 TB 诊断之前的个人时间或在 TB 诊断后超过 6 个月的时间与不良病毒学结果无关。
ART 期间发生的活动性结核病与 TB 诊断后 6 个月内的不良病毒学结果密切相关。尽管潜在的机制尚待确定,但活动性结核病患者可能受益于病毒学监测和治疗依从性支持。